TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Clinical trial NCT06001762 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06001762
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-05
- Primary completion
- 2025-01-22
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.